
ConvaTec Group
CNVVY | OTC
$13.18
$0.00 (0.00%)
Nov 2, 2026, 9:31 AM ET · Market open
Company Profile
ConvaTec Group Plc operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a wide range of healthcare products. The company offers advanced wound care and skin protection solutions, tailored for the effective management of both acute and chronic wounds arising from diverse conditions such as diabetes, immobility, venous disease, traumatic injuries, burns, or complications following surgery. Furthermore, ConvaTec provides comprehensive ostomy care, including specialized devices, accessories, and support services for individuals living with a stoma, often necessitated by conditions like colorectal or bladder cancer, inflammatory bowel disease, obesity, among other medical reasons. Its product portfolio also extends to continence and critical care. This encompasses intermittent urinary catheters and solutions for managing bladder control issues linked to spinal cord injuries, multiple sclerosis, spina bifida, and various other urological disorders. Additionally, the firm supplies medical devices and products specifically designed for use in intensive care units (ICUs) and broader hospital settings. ConvaTec develops sophisticated systems for handling acute fecal incontinence, as well as for precise monitoring of urine production output and intra-abdominal pressure. A diverse array of disposable medical devices is also provided, featuring wound drainage systems, urine collection bags and catheters, equipment for airway management and oxygen/aerosol therapy, suction handles and tubing, gastroenterology tubes, and securement devices. The company is also a supplier of disposable infusion sets to manufacturers of insulin pumps for diabetic patients, and similar sets for pumps employed in continuous infusion treatments for other medical conditions. ConvaTec serves a broad spectrum of clients, including healthcare providers, patients, and other manufacturers. Its products reach both hospital and home healthcare markets, distributed through direct sales, as well as via distributors and wholesalers, targeting pharmacies, hospitals, and various acute and post-acute healthcare service providers. Established in 1978, the company's corporate headquarters are located in Reading, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Jonathan Mason | Chief Executive Officer & Director |
| Anne Belcher | President & Chief Operating Officer of Global Emerging Markets |
| Bruno Pinheiro | President & Chief Operating Officer of Ostomy Care |
| Emma Rose | EVP & Chief People Officer |
| Fiona Victoria Ryder | Chief Financial Officer & Director |
| Kjersti Grimsrud Biotechnology | President & Chief Operating Officer of Infusion Care |
| Dave Ubachs | Chief Digital & Information Officer |
| David Shepherd | Chief Commercial Officer |
| Evelyn Douglas | EVP and Chief Strategy & Business Development Officer |
| James Edward Spencer Kerton | EVP, General Counsel & Company Secretary |
| Peter Jarvis | Chief Operations Officer |
ConvaTec Group

| Country | United Kingdom |
| IPO Date | Jan 26, 2017 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 10,910 |
| CEO | Jonathan Peter Mason |
Contact Details
20 Eastbourne Terrace London,
GL W2 6LG United Kingdom
Stock Details
| Ticker Symbol | CNVVY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 21244X109 |
| ISIN Number | US21244X1090 |
| SIC Code | n/a |
Recent News
- 12 days ago / proactiveinvestors.comJP Morgan says ConvaTec guidance looks increasingly secure ahead of trading update
- 27 days ago / businesswire.comConvatec Survey Challenges Assumptions About Leakage in Ostomy Care
- 1 month ago / businesswire.comConvatec Expands Cure™ Portfolio With Launch of Cure Aqua™, Bringing Greater Choice to People Who Catheterize
- 3 months ago / seekingalpha.comConvatec Group PLC (CNVVY) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comConvaTec Group H1 Earnings Call Highlights
- 3 months ago / reuters.comUK's Convatec expects higher second-half margin, launches $200 million buyback
Add to Watchlist
Select watchlists to add or remove CNVVY